Literature DB >> 35587703

Ceftriaxone-induced leukocytoclastic vasculitis: a case report and literature review of antibiotic-induced leukocytoclastic vasculitis.

Aseel A Almasoudi1, Eman S Bablghaith1, Samaher I Alaauldeen1, Ayman M Falemban1, Ahlam A Sherbeeni1, Adeeb A Bulkhi1,2.   

Abstract

Leukocytoclastic vasculitis (hypersensitivity vasculitis) is defined as small blood vessel inflammation with skin or other systemic manifestations due to infections, drugs, or neoplastic disease. This clinical case report highlights an association between ceftriaxone and leukocytoclastic vasculitis in a 49-year-old female patient with a history of penicillin allergy, on mirtazapine for anxiety disorder. Articles concerning antibiotic-induced leukocytoclastic vasculitis are also reviewed. The patient reported a symptom of upper respiratory tract infection and fever 5 days previously for which she received ceftriaxone for 2 days before presenting to the emergency department with a pruritic skin rash in the upper and lower extremities and swollen lips for 1 day. The rash was erythematous, maculopapular, itchy, and non-tender, with no mucus membrane involvement. Laboratory investigations revealed leukocytosis (white blood cells, 22.3 × 109/L) that was mainly eosinophilic (18.4%). The patient was administered prednisolone and antihistamine after stopping ceftriaxone empirically. A skin biopsy confirmed the diagnosis of leukocytoclastic vasculitis. Significant clinical improvement was observed after treatment initiation. Upon follow-up, the skin rash was resolved entirely with no scars; however, there was skin-peeling over the lower extremities. Recognition of antibiotic-induced leukocytoclastic vasculitis is crucial as many classes of antibiotics can contribute to this condition. Continuation of the offending drug may lead to life-threatening complications.

Entities:  

Keywords:  Antibiotic-induced leukocytoclastic vasculitis; antibiotic; hypersensitivity vasculitis; leukocytoclastic vasculitis; leukocytosis; small-vessel vasculitis

Mesh:

Substances:

Year:  2022        PMID: 35587703      PMCID: PMC9127858          DOI: 10.1177/03000605221097768

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.573


  75 in total

1.  Vascular fibrinoid in cutaneous "allergic" arteriolitis.

Authors:  M RUITER
Journal:  J Invest Dermatol       Date:  1962-02       Impact factor: 8.551

2.  Cutaneous vasculitis associated with tuberculosis and its treatment.

Authors:  C H Chan; Y W Chong; A J Sun; G B Hoheisel
Journal:  Tubercle       Date:  1990-12

Review 3.  Necrotizing vasculitis.

Authors:  W M Sams
Journal:  J Am Acad Dermatol       Date:  1980-07       Impact factor: 11.527

Review 4.  Small-vessel vasculitis.

Authors:  J C Jennette; R J Falk
Journal:  N Engl J Med       Date:  1997-11-20       Impact factor: 91.245

5.  Drug associated cutaneous vasculitis in adults in northwestern Spain.

Authors:  C García-Porrúa; M A González-Gay; L López-Lázaro
Journal:  J Rheumatol       Date:  1999-09       Impact factor: 4.666

Review 6.  Clinical approach to cutaneous vasculitis.

Authors:  Ko-Ron Chen; J Andrew Carlson
Journal:  Am J Clin Dermatol       Date:  2008       Impact factor: 7.403

7.  Nephrotoxicity and purpura associated with levofloxacin.

Authors:  Giuseppe Famularo; Claudio De Simone
Journal:  Ann Pharmacother       Date:  2002-09       Impact factor: 3.154

Review 8.  Leukocytoclastic Vasculitis with Systemic Involvement Associated with Ciprofloxacin Therapy: Case Report and Review of the Literature.

Authors:  Bruno Morgado; Catarina Madeira; Joana Pinto; Joana Pestana
Journal:  Cureus       Date:  2016-11-28

9.  Cutaneous leukocytoclastic vasculitis associated with levofloxacin therapy.

Authors:  Dana M Blyth; Elizabeth Markelz; Jason F Okulicz
Journal:  Infect Dis Rep       Date:  2012-01-30

10.  Oxacillin-induced leukocytoclastic vasculitis.

Authors:  Meric Mericliler; Aya Shnawa; Dalya Al-Qaysi; Jorge Fleisher; Andrew Moraco
Journal:  IDCases       Date:  2019-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.